Short Interest in HilleVax, Inc. (NASDAQ:HLVX) Grows By 10.2%

HilleVax, Inc. (NASDAQ:HLVXGet Free Report) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 474,900 shares, a growth of 10.2% from the February 29th total of 431,000 shares. Based on an average trading volume of 127,400 shares, the days-to-cover ratio is presently 3.7 days. Approximately 3.2% of the company’s shares are sold short.

HilleVax Price Performance

Shares of HLVX opened at $15.90 on Tuesday. HilleVax has a 12-month low of $9.94 and a 12-month high of $20.22. The business’s fifty day moving average is $16.27 and its 200 day moving average is $14.59. The company has a quick ratio of 10.62, a current ratio of 10.62 and a debt-to-equity ratio of 0.10. The stock has a market cap of $790.23 million, a P/E ratio of -5.24 and a beta of 0.65.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $28.00 target price on shares of HilleVax in a research report on Thursday, March 21st.

Check Out Our Latest Analysis on HLVX

Insider Buying and Selling

In other HilleVax news, insider Robert Hershberg sold 11,597 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total transaction of $173,143.21. Following the sale, the insider now directly owns 953,831 shares in the company, valued at approximately $14,240,696.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Robert Hershberg sold 11,597 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total transaction of $173,143.21. Following the transaction, the insider now directly owns 953,831 shares in the company, valued at $14,240,696.83. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Shane Maltbie sold 3,576 shares of the business’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $14.93, for a total transaction of $53,389.68. Following the transaction, the chief financial officer now owns 40,656 shares in the company, valued at $606,994.08. The disclosure for this sale can be found here. Insiders have sold 66,039 shares of company stock valued at $986,288,022 in the last 90 days. 29.30% of the stock is owned by insiders.

Institutional Investors Weigh In On HilleVax

A number of institutional investors and hedge funds have recently bought and sold shares of HLVX. Vanguard Group Inc. raised its holdings in shares of HilleVax by 27.0% during the 4th quarter. Vanguard Group Inc. now owns 1,464,840 shares of the company’s stock valued at $23,511,000 after buying an additional 310,973 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of HilleVax by 17.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 20,314 shares of the company’s stock valued at $326,000 after buying an additional 2,952 shares during the period. American International Group Inc. boosted its position in shares of HilleVax by 23.0% during the fourth quarter. American International Group Inc. now owns 13,031 shares of the company’s stock valued at $209,000 after purchasing an additional 2,437 shares in the last quarter. Barclays PLC boosted its position in shares of HilleVax by 526.1% during the fourth quarter. Barclays PLC now owns 39,908 shares of the company’s stock valued at $640,000 after purchasing an additional 33,534 shares in the last quarter. Finally, Voya Investment Management LLC bought a new stake in shares of HilleVax during the fourth quarter valued at approximately $166,000. 86.42% of the stock is owned by hedge funds and other institutional investors.

About HilleVax

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

Recommended Stories

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.